Aerovate Therapeutics, Inc. (AVTE) Misses Q3 EPS by 2c

Aerovate Therapeutics, Inc. (NASDAQ: AVTE) reported Q3 EPS of ($0.71), $0.02 worse than the analyst estimate of ($0.69).

For earnings history and earnings-related data on Aerovate Therapeutics, Inc. (AVTE) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Marvell (MRVL) Stock: Risk/Reward Skewed to the Upside Near-Term Following Selloff, Says Analyst
• Chagee Holdings (CHA) Tops Q2 EPS by 3c